SEC Form 4 · accession 0001179110-18-012518
Axogen, Inc. · AXGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isabelle Billet
Officer — Chief Strategy and BD Officer
Period of report
Nov 1, 2018
Accepted (ET)
Nov 5, 2018 · 7:47 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000805928
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to purchase)F1 | $38.25 | Nov 1, 2018 | A | 40,000 | A | — | Nov 1, 2028 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on November 1, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on November 1, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.